Screening for antifungal peptides and their modes of action in Aspergillus nidulans.
Many short cationic peptides have been identified as potent antimicrobial agents, but their modes of action are not well understood. Peptide synthesis on cellulose membranes has resulted in the generation of peptide libraries, while high-throughput assays have been developed to test their antibacterial activities. In this paper a microtiter plate-based screening method for fungi has been developed and used to test nine antibacterial peptides against the model fungus Aspergillus nidulans. Microscopical studies using sublethal peptide concentrations caused defects in polarized growth, including increased branch formation and depolarized hyphae. We characterized the mode of action for one of our target peptides, Sub5 (12 amino acids), which has already been shown to possess pharmacological potential as an antibacterial agent and is able to interact with ATP and ATP-dependent enzymes. The MIC for A. nidulans is 2 μg/ml, which is in the same range as the MICs reported for bacteria. Fluorescein isothiocyanate (FITC)-labeled Sub5 targeted the cytoplasmic membrane, particularly hyphal tips, and entered the cytoplasm after prolonged exposure, independent of endocytosis. Interestingly, Sub5 peptide treatment disturbed sterol-rich membrane domains, important for tip growth, at hyphal tips. A very similar peptide, FITC-P7, also accumulated on the cell membrane but did not have antibacterial or antifungal activity, suggesting that the cytoplasmic membrane is a first target for the Sub5 peptide; however, the antifungal activity seems to be correlated with the ability to enter the cytoplasm, where the peptides might act on other targets.
Mania
Daniel
D
Karlsruhe Institute of Technology, Institute for Applied Biosciences, Department of Microbiology, Hertzstrasse 16, D-76187 Karlsruhe, Germany.
Hilpert
Kai
K
Ruden
Serge
S
Fischer
Reinhard
R
Takeshita
Norio
N
D000935:Antifungal Agents / Q000302:isolation & purification / Q000494:pharmacology*; D023181:Antimicrobial Cationic Peptides / Q000302:isolation & purification / Q000494:pharmacology*; D001233:Aspergillus nidulans / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D025301:Hyphae / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D008856:Microscopy, Fluorescence; D025282:Mycelium / Q000187:drug effects; D010641:Phenotype; D011523:Protoplasts / Q000187:drug effects
D000935:Antifungal Agents; D023181:Antimicrobial Cationic Peptides